Ix Biopharma Ltd., of Singapore, reported results of a pivotal bioequivalence study comparing its sildenafil wafer (Pheonix) with the reference drug (Viagra, Pfizer Inc.), approved to treat erectile dysfunction. The study achieved its primary objective by demonstrating that the sublingual wafer formulation of Pheonix had a similar rate and extent of drug absorption as the reference drug. Pheonix was well-tolerated and there were no serious adverse events reported. The company plans to apply for registration of Pheonix in Australia.